インシリコ創薬の市場規模、シェア、成長分析、製品別、ワークフロー別、標的治療領域別、エンドユーザー別、地域別 - 産業予測、2025～2032年

インシリコ創薬の世界市場規模は、2023年に29億米ドルと評価され、予測期間（2025年～2032年）のCAGRは11.0%で、2024年の32億2,000万米ドルから2032年には74億2,000万米ドルに成長する見通しです。

インシリコ創薬市場は、創薬データ量の増加とバイオインフォマティクス技術の進歩により、2023年から2030年にかけて大きく成長する見通しです。同市場は、創薬ターゲットの同定、候補分子の開発、結合特性の最適化にインシリコ戦略を活用しています。再入院率や医療ミスを最小限に抑えることに焦点を当てたバイオマーカー同定の増加が予測され、市場の拡大をさらに後押ししています。計算生物学とコスト効率の高いインシリコ設計サービスにおける著しい進歩が、市場の魅力を高めています。しかし、価格圧力やオープンソースソフトウェアの利用可能性といった課題は、成長を妨げる可能性があります。全体として、製薬企業における創薬プロジェクトや研究活動の急増は、市場関係者に大きなビジネスチャンスをもたらしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

インシリコ創薬市場規模：製品別

• 市場概要
• サービスとしてのソフトウェア
• ソフトウェア
• サービスとしてのコンサルティング

インシリコ創薬市場規模：ワークフロー別

• 市場概要
• 前臨床試験
• 発見
• 臨床試験

インシリコ創薬市場規模：標的治療領域別

• 市場概要
• 代謝障害
• HIV
• 感染症
• 筋骨格障害
• 精神障害
• 神経疾患
• 腫瘍性疾患

インシリコ創薬市場規模：エンドユーザー別

• 市場概要
• 契約調査機関
• 製薬・バイオ医薬品企業
• 学術研究機関
• その他

インシリコ創薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Atomwise（USA）
• Insilico Medicine（Hong Kong）
• Iktos（France）
• Cradle（USA）
• BenevolentAI（UK）
• Schrodinger（USA）
• Cloud Pharmaceuticals（USA）
• Numerate（USA）
• XtalPi（China）
• BenevolentAI（UK）
• Biovista（USA）
• Certara（USA）
• Cloud Pharmaceuticals（USA）
• XtalPi（China）
• Atomwise（USA）
• Exscientia（UK）
• Insilico Medicine（Hong Kong）
• Iktos（France）
• Cradle（USA）

結論と推奨事項

Global Insilico Drug Discovery Market size was valued at USD 2.9 billion in 2023 and is poised to grow from USD 3.22 billion in 2024 to USD 7.42 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The in-silico drug discovery market is poised for significant growth from 2023 to 2030, driven by the increasing volume of drug discovery data and advancements in bioinformatics technologies. This market leverages in-silico strategies to identify drug targets, develop candidate molecules, and optimize their binding properties. The projected rise in biomarker identification, coupled with a focus on minimizing readmission rates and medical errors, further supports market expansion. Significant advancements in computational biology and cost-effective in-silico designing services enhance market appeal. However, challenges such as pricing pressures and the availability of open-source software may hinder growth. Overall, the surge in drug discovery projects and research activity within pharmaceutical organizations presents considerable opportunities for market players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insilico Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insilico Drug Discovery Market Segmental Analysis

Global Insilico Drug Discovery Market is segmented by Product, Workflow, Target Therapeutic Area, End User and region. Based on Product, the market is segmented into Software-as-a-Service, Software and Consultancy-as-a-Service. Based on Workflow, the market is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. Based on Target Therapeutic Area, the market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. Based on End User, the market is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insilico Drug Discovery Market

The global in-silico drug discovery market is expected to experience significant growth in the coming years, primarily driven by advancements in biomarker identification. Additionally, there is a growing emphasis on reducing readmission rates and minimizing medical errors, which further fuels this demand. Innovations in computational technologies within computational biology and enhancements in in-silico drug discovery methodologies also contribute substantially to market expansion. These factors collectively create a robust environment that encourages the adoption of in-silico approaches, ultimately transforming the drug discovery landscape and meeting the evolving needs of the healthcare sector.

Restraints in the Global Insilico Drug Discovery Market

A significant challenge facing the Global Insilico Drug Discovery market is its inherently short lifespan, which serves as a primary restraint. The analysis durations for this technology can vary from tens to hundreds of nanoseconds, contingent upon the complexity of the systems being evaluated and the computational resources available. This brevity poses a substantial issue, as the time frames-ranging from a few milliseconds to several seconds-are often insufficient for precise predictions of protein folding. Consequently, this limitation may hinder the sampling of an adequate number of protein conformations, potentially impacting the accuracy and reliability of drug discovery outcomes.

Market Trends of the Global Insilico Drug Discovery Market

The global in-silico drug discovery market is witnessing significant growth, primarily fueled by the rising adoption of cloud-based solutions that enhance computational capabilities for pharmaceutical researchers. This trend allows for scalable and adaptive computing environments, empowering researchers with virtually unlimited processing power to accelerate drug development processes. Notably, platforms like BT's Cloud Compute life sciences service offer tailored applications that cater to various stages of the drug discovery value chain, enabling seamless compatibility across diverse pipelines. As companies increasingly prioritize tailored solutions, the market is set to expand, driving innovation and efficiency in drug discovery efforts.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Insilico Drug Discovery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Software-as-a-Service
• Software
• Consultancy-as-a-Service

Global Insilico Drug Discovery Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Pre-Clinical Tests
• Discovery
• Clinical Tests

Global Insilico Drug Discovery Market Size by Target Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Metabolic disorders
• HIV
• Infectious diseases
• Musculoskeletal disorders
• Mental disorders
• Neurological disorders
• Oncological disorders

Global Insilico Drug Discovery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Contract Research Organizations
• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

Global Insilico Drug Discovery Market Size & CAGR (2025-2032)

• North America (Product, Workflow, Target Therapeutic Area, End User)
  • US
  • Canada
• Europe (Product, Workflow, Target Therapeutic Area, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Workflow, Target Therapeutic Area, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Workflow, Target Therapeutic Area, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Workflow, Target Therapeutic Area, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Atomwise (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iktos (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cradle (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Schrodinger (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cloud Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numerate (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XtalPi (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovista (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Certara (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cloud Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XtalPi (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atomwise (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exscientia (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iktos (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cradle (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations